Jeff Yass’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-111,005
| Closed | -$2.24M | – | 14377 |
|
|
2021
Q3 | $2.24M | Sell |
111,005
-41,688
| -27% | -$1.15M | ﹤0.01% | 5588 |
|
|
2021
Q2 | $5.7M | Buy |
152,693
+108,476
| +245% | +$3.32M | ﹤0.01% | 3803 |
|
|
2021
Q1 | $1.13M | Sell |
44,217
-18,220
| -29% | -$465K | ﹤0.01% | 7403 |
|
|
2020
Q4 | $1.38M | Sell |
62,437
-131,270
| -68% | -$2.89M | ﹤0.01% | 5944 |
|
|
2020
Q3 | $3.48M | Buy |
193,707
+171,848
| +786% | +$3.56M | ﹤0.01% | 3616 |
|
|
2020
Q2 | $555K | Sell |
21,859
-4,300
| -16% | -$92.6K | ﹤0.01% | 7156 |
|
|
2020
Q1 | $481K | Buy |
+26,159
| New | +$508K | ﹤0.01% | 7025 |
|
|
2019
Q4 | – | Sell |
-26,862
| Closed | -$541K | – | 11013 |
|
|
2019
Q3 | $386K | Sell |
26,862
-9,318
| -26% | -$133K | ﹤0.01% | 7816 |
|
|
2019
Q2 | $570K | Buy |
+36,180
| New | +$492K | ﹤0.01% | 7014 |
|
|
2018
Q2 | – | Sell |
-86,291
| Closed | -$1.08M | – | 10722 |
|
|
2018
Q1 | $825K | Sell |
86,291
-13,083
| -13% | -$141K | ﹤0.01% | 5655 |
|
|
2017
Q4 | $897K | Buy |
+99,374
| New | +$731K | ﹤0.01% | 5457 |
|
|
2016
Q3 | – | Sell |
-11,130
| Closed | -$33K | – | 9283 |
|
|
2016
Q2 | $33K | Buy |
+11,130
| New | +$45.7K | ﹤0.01% | 8310 |
|
Other funds holding DRNA
Jeff Yass's DRNA Position: Q4 2021 in Review
Jeff Yass sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 111,005 shares — an estimated $2.24M sold.
Jeff Yass first reported a position in DRNA in Q2 2016 and held it in 12 quarters. The position peaked at $5.7M in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.
- Jeff Yass reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
- Jeff Yass sold 111,005 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $2.24M.
- Jeff Yass first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2016 and held it in 12 quarters.
- Jeff Yass's Dicerna Pharmaceuticals, Inc. position peaked at $5.7M in Q2 2021.
- 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.
Based on Susquehanna International Group's 13F filing for Q4 2021, filed 14 Feb 2022.